

## Datasheet: HCA305

<b>Description:</b>	HUMAN ANTI RANIBIZUMAB
<b>Specificity:</b>	RANIBIZUMAB
<b>Other names:</b>	Lucentis
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD16746_hlgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.

### Preparation

Purified IgG prepared by affinity chromatography on Protein A

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

### Immunogen

Ranibizumab

### Specificity

**Human Anti-Ranibizumab Antibody, clone AbD16746\_hlgG1** is a paratope specific, inhibitory anti-idiotypic antibody in IgG1 format that recognizes the monoclonal antibody

drug ranibizumab. The antibody does not recognize recombinant human vascular endothelial growth factor A (VEGF-A) or ranibizumab when in complex with recombinant human VEGF-A.

Clone AbD16746\_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a control or calibration standard in an anti-drug antibody (ADA) assay.

This antibody also recognizes the monoclonal antibody drug bevacizumab.

Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.

[View a summary of all anti-ranibizumab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of AbD16746_hlgG1 was measured as $K_D = 2$ nM by real time, label free molecular interaction analysis on immobilized bevacizumab.
<b>ELISA</b>	Clone AbD16746_hlgG1 can be used in a direct or indirect ELISA or as a calibrator for the set-up of an anti-drug antibody assay.  Protocol: <a href="#">ADA bridging ELISA</a>
<b>Storage</b>	This product is shipped at ambient temperature. It is recommended to aliquot and store at $-20^{\circ}\text{C}$ on receipt. When thawed, aliquot the sample as needed. Keep aliquots at $2-8^{\circ}\text{C}$ for short term use (up to 4 weeks) and store the remaining aliquots at $-20^{\circ}\text{C}$ .  Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See <a href="http://bio-rad.com/en-us/trademarks">bio-rad.com/en-us/trademarks</a> for details. Lucentis is a trademark of Genentech.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: 10094: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf</a>
<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro

testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Useful Reagents

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M391821:211015'

**Printed on 21 Mar 2022**

---

© 2022 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)